Aristides Capital LLC Acquires Shares of 8,000 Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Aristides Capital LLC bought a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 8,000 shares of the biopharmaceutical company’s stock, valued at approximately $202,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its stake in Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 878 shares in the last quarter. Headlands Technologies LLC purchased a new position in Celldex Therapeutics during the 4th quarter valued at about $81,000. KBC Group NV increased its position in shares of Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 1,647 shares during the period. AlphaQuest LLC lifted its holdings in shares of Celldex Therapeutics by 171.0% in the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 2,705 shares in the last quarter. Finally, E Fund Management Co. Ltd. purchased a new stake in Celldex Therapeutics in the 4th quarter worth approximately $273,000.

Analyst Ratings Changes

A number of brokerages recently issued reports on CLDX. UBS Group assumed coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They issued a “buy” rating and a $44.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research report on Friday, February 28th. The Goldman Sachs Group dropped their price target on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. Finally, Morgan Stanley assumed coverage on Celldex Therapeutics in a report on Thursday, March 20th. They set an “overweight” rating and a $46.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $54.33.

Celldex Therapeutics Stock Down 0.3 %

Shares of Celldex Therapeutics stock opened at $15.73 on Tuesday. The firm has a market cap of $1.04 billion, a PE ratio of -6.12 and a beta of 1.59. Celldex Therapeutics, Inc. has a 12-month low of $14.61 and a 12-month high of $47.00. The company’s fifty day simple moving average is $21.01 and its two-hundred day simple moving average is $25.16.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The business had revenue of $1.18 million for the quarter, compared to analysts’ expectations of $1.25 million. As a group, sell-side analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.